Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA asks UroMed for more information:

This article was originally published in Clinica

Executive Summary

UroMed has received a request from the US FDA for more information on its Reliance urinary control insert, which has been granted expedited review status. An updated 510(k) was filed with the agency in August, after the FDA had requested additional information on the original application filed in December 1994. UroMed says it will file a response within 60 days, adding that it remains uncertain whether the FDA will accept the 510(k) or will require a PMA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel